Replies to post #13337 on Biotech Values

[aslan2772]

Re: ATryn, sepsis, and burns

Dew, one of the possiblilties eluded to by the results of the KyberSept trial is the possibility of loss of efficacy when AT III and Heparin are co-administered. If this is the case, could it not be a potential stumbling block towards the use of ATryn in CABG, another indication GTCB is pursuing (assuming that AT alpha interacts similarily with Heparin)? Do you know if Heparin is used in burn victims?

Of course, I'm only testing the soundness of MGMT's claim that they see a potential 500-700M$ market for ATryn. Other than the risk of adverse politics against the first transgenic medical products, I like the platform.